secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001213900-24-004946
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity enters $440K convertible note with 3i, LP; Series A conversion price cut to $0.4476
--------------------------------------------------------------------------------

- Issued $440K principal senior convertible note to 3i, LP at $400K purchase price (10% OID), due Jan 18, 2025, 8% interest.
- Conversion price set at $0.4476 per share; Purchaser limited to 4.99% beneficial ownership cap.
- Second closing of $440K note at same terms may be required by company; potential additional $600K notes.
- Series A Preferred Stock conversion price amended from $1.00 to $0.4476 via Fifth Amendment.
- Proceeds used for accounts payable and working capital; negative covenants restrict further debt over $250K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/ea191856-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-004946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer